HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Reaction

Dimethylformamide → 3-(4-Methyl-1H-imidazol-1-yl)-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-5-(trifluoromethyl)benzamide bis(trifluoroacetate)

HRID 1894871
Print

Reaction equation

HRID 1894871 reaction equation
[CH3:1][C:2]1[N:3]=[CH:4][N:5]([C:7]2[CH:8]=[C:9]([CH:13]=[C:14]([C:16]([F:19])([F:18])[F:17])[CH:15]=2)[C:10]([OH:12])=O)[CH:6]=1.F[P-](F)(F)(F)(F)F.C[N+](C)=C(N(C)C)[O:30]N1C2N=CC=CC=2N=N1.C(N(CC)C(C)C)(C)C.[CH3:53][C:54]1[CH:60]=[CH:59][C:57]([NH2:58])=[CH:56][C:55]=1[C:61]1[CH:69]=[C:68]2[C:64]([C:65]3[CH:73]=[N:72][CH:71]=[N:70][C:66]=3[NH:67]2)=[CH:63][CH:62]=1.CN([CH:77]=[O:78])C>>[F:17][C:16]([F:19])([F:18])[C:77]([OH:78])=[O:30].[F:17][C:16]([F:19])([F:18])[C:77]([OH:78])=[O:30].[CH3:1][C:2]1[N:3]=[CH:4][N:5]([C:7]2[CH:8]=[C:9]([CH:13]=[C:14]([C:16]([F:19])([F:18])[F:17])[CH:15]=2)[C:10]([NH:58][C:57]2[CH:59]=[CH:60][C:54]([CH3:53])=[C:55]([C:61]3[CH:69]=[C:68]4[C:64]([C:65]5[CH:73]=[N:72][CH:71]=[N:70][C:66]=5[NH:67]4)=[CH:63][CH:62]=3)[CH:56]=2)=[O:12])[CH:6]=1
ParticipantsProcedureWorkupSources & evidenceReaction notes

Participants

6

Reactant 5

HCID 6228DimethylformamideHCID 81531DiisopropylethylamineHCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)HCID 469002413-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzoic acidHCID 690464994-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)aniline

Product 1

HCID 866219583-(4-Methyl-1H-imidazol-1-yl)-N-[4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)phenyl]-5-(trifluoromethyl)benzamide bis(trifluoroacetate)

Procedure

To 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzoic acid (39 mg, 0.14 mmol, prepared according to WO2004005281) was added DMF (0.93 mL) followed by N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (66.5 mg, 0.175 mmol) and N,N-diisopropylethylamine (DIPEA) (30.5 μL, 0.175 mmol). This solution was stirred at ambient temperature for 15 minutes, then 4-methyl-3-(9H-pyrimido[4,5-b]indol-7-yl)aniline (40.0 mg, 0.146 mmol) was added. The reaction was held at ambient temperature until LCMS indicated complete reaction, typically 1-2 hours. The reaction was partitioned between water and EtOAc and the organic phase was washed with water and saturated aqueous NaCl, then dried (MgSO4) and evaporated to dryness to leave the crude product. This was purified by preparative LCMS to recover the product as a bis-TFA salt (60.3 mg, 55%). 1H NMR (400 MHz, DMSO): δ 13.0 (bs, 1H), 10.67 (s, 1H), 9.63 (s, 1H), 9.60 (s, 1H), 9.12 (s, 1H), 8.60 (s, 1H), 8.42 (m, 2H), 8.37 (d, 1H), 8.15 (s, 1H), 7.77 (m, 2H), 7.56 (s, 1H), 7.43 (dd, 1H), 7.37 (d, 1H), 2.33 (s, 3H), 2.26 (s, 3H). MS (EI) m/z=527 (M+H).

Workup

  1. customwas held at ambient temperature until LCMS
  2. customreaction, typically 1-2 hours
  3. customThe reaction was partitioned between water and EtOAc
  4. washthe organic phase was washed with water and saturated aqueous NaCl
  5. dry with materialdried (MgSO4)
  6. customevaporated to dryness

Sources & evidence

ORD record
ord-59020a56a9734ee08655758be62c85ca
Source dataset
uspto-grants-2013_08
DOI
10.6084/m9.figshare.5104873.v1
Patent number
US08513270B2

Reaction notes

On this pageParticipantsProcedureWorkupSources & evidenceReaction notes